Engene Holdings WT (ENGNW)

$1.97 -0.13 (-6.19%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -99.92M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 815
Avg Vol 5,100
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 57%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

Phone: 514 332 4888
Address:
4868 Rue Levy, Suite 220, Montreal, Canada
Latest News on ENGNW
enGene to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:00 AM EST - 5 days ago

enGene to Participate in Upcoming Investor Conferences

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 8:00 AM EST - 21 days ago

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

enGene: Two Major Catalysts On Deck For 2nd Half Of 2026

Jan 27, 2026, 3:17 PM EST - 4 weeks ago

enGene: Two Major Catalysts On Deck For 2nd Half Of 2026

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

Jan 20, 2026, 5:35 PM EST - 5 weeks ago

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

HTGC

enGene Reports Full Year 2025 Financial Results and Provides Business Update

Dec 22, 2025, 4:03 PM EST - 2 months ago

enGene Reports Full Year 2025 Financial Results and Provides Business Update

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

Dec 2, 2025, 7:30 AM EST - 3 months ago

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 3 months ago

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Nov 13, 2025, 12:27 AM EST - 3 months ago

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 4:01 PM EST - 3 months ago

enGene Announces Proposed Public Offering of Common Shares

enGene Holdings: Still A Buy After A Massive Surge

Nov 12, 2025, 9:52 AM EST - 3 months ago

enGene Holdings: Still A Buy After A Massive Surge

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript

Nov 11, 2025, 1:41 PM EST - 3 months ago

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

Nov 11, 2025, 10:37 AM EST - 3 months ago

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Nov 11, 2025, 7:30 AM EST - 3 months ago

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Nov 10, 2025, 4:05 PM EST - 3 months ago

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

enGene Named a BioSpace 2026 Best Places to Work Winner

Nov 4, 2025, 1:35 PM EST - 4 months ago

enGene Named a BioSpace 2026 Best Places to Work Winner

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Oct 1, 2025, 4:03 PM EDT - 5 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Sep 30, 2025, 7:30 AM EDT - 5 months ago

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 11, 2025, 4:03 PM EDT - 5 months ago

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 5:25 PM EDT - 5 months ago

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Sep 3, 2025, 7:30 AM EDT - 6 months ago

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Jul 8, 2025, 8:00 AM EDT - 8 months ago

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Jun 25, 2025, 8:00 AM EDT - 8 months ago

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

Jun 18, 2025, 4:16 PM EDT - 8 months ago

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 12, 2025, 8:00 AM EDT - 9 months ago

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

enGene Announces the Resignation of its Chief Medical Officer

Jun 4, 2025, 8:30 AM EDT - 9 months ago

enGene Announces the Resignation of its Chief Medical Officer

enGene to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 9 months ago

enGene to Present at the Jefferies Global Healthcare Conference

enGene Names Amy Pott as Chief Global Commercialization Officer

May 28, 2025, 7:30 AM EDT - 9 months ago

enGene Names Amy Pott as Chief Global Commercialization Officer

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 11 months ago

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 1 year ago

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene to Participate in the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 1 year ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

Feb 27, 2025, 4:20 AM EST - 1 year ago

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Jan 30, 2025, 8:00 AM EST - 1 year ago

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Dec 19, 2024, 4:05 PM EST - 1 year ago

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

Dec 15, 2024, 4:53 AM EST - 1 year ago

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 22, 2024, 4:05 PM EDT - 1 year ago

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Oct 21, 2024, 8:45 AM EDT - 1 year ago

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Sep 26, 2024, 6:30 AM EDT - 1 year ago

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Sep 10, 2024, 4:33 PM EDT - 1 year ago

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2024, 4:05 PM EDT - 1 year ago

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Jul 24, 2024, 6:30 AM EDT - 1 year ago

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jun 14, 2024, 7:01 AM EDT - 1 year ago

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024, 4:05 PM EDT - 1 year ago

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

May 2, 2024, 4:05 PM EDT - 1 year ago

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:56 AM EDT - 2 years ago

/C O R R E C T I O N -- enGene Inc./

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

Apr 9, 2024, 8:00 AM EDT - 2 years ago

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Mar 11, 2024, 5:16 PM EDT - 2 years ago

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

enGene To Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 7:00 AM EST - 2 years ago

enGene To Present at the Leerink Partners Global Biopharma Conference